echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Innovative head and neck cancer therapy that inhibits RAS signaling is recognized as a breakthrough therapy by the FDA

    Innovative head and neck cancer therapy that inhibits RAS signaling is recognized as a breakthrough therapy by the FDA

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Kura Oncology announced today that its investigational therapy tipifarnib has received a breakthrough therapy designation granted by the U.


    HNSCC is the seventh most common cancer in the world, with more than 885,000 new cases each year.


    HRAS gene mutation mediates tumor proliferation and drug resistance in many solid tumors, and is an important target in the field of anti-cancer drug development.


    This breakthrough therapy designation is based on data from a phase 2 clinical trial called RUN-HN.


    "We are very pleased that the FDA has granted tipifarnib a breakthrough therapy designation, which is an affirmation of its therapeutic potential.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.